Work

SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps3652

Authors: Amita Patnaik, Funda Meric-Bernstam, Caio Max Sao Pedro Rocha Lima, Francisco Robert, Afshin Dowlati, Hedy L. Kindler, Diwakar Davar, Steven Francis Powell, Phillip M. Garfin, Ani Sarkis Balmanoukian

Institutions: South Texas Accelerated Research Therapeutics, The University of Texas MD Anderson Cancer Center, Atrium Health Wake Forest Baptist, NRG Oncology, Wake Forest Baptist Comprehensive Cancer Center, University of Alabama at Birmingham, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, University of Chicago, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Sanford Health, Seagen (United States), Angeles Clinic and Research Institute

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3030544101

Cites:

Cited by: 7

Related to: 10